MedTrace Logo

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

NCT05509855 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2024-11-20

No results posted yet for this study

Summary

This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.

Conditions

  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Lymphoblastic Lymphoma

Interventions

GENETIC

Genetic: WU-CART-007

No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy

Sponsors & Collaborators

  • Wugen, Inc.

    lead INDUSTRY

Principal Investigators

  • Cherry Thomas, MD · Wugen, Inc.

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-22
Primary Completion
2037-07-01
Completion
2037-07-01
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05509855 on ClinicalTrials.gov